The recently opened Alliance A082002 trial will randomize patients with PD-L1 negative advanced NSCLC to systemic therapy with or without SBRT (24 Gy in 3 fractions) to a single tumor site with a primary endpoint of improved overall survival [78,79]. The gene discussed is CD274; the disease is neoplasm.